Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma
2017-000498-35Phase 2Active
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) and Hodgkin lymphoma (HL), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Modified progression-free survival rate at 2 years. Started Nov 2018; status: active.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2017-000498-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000498-35.